Table 1.
Summary of analysis of studies reporting overall survival and mortality disparities included in review
| SURVIVAL | |||||||
|---|---|---|---|---|---|---|---|
| Author Year | Outcome | Sample | Data Source | Age Range | Age Comparisons | Staging | Racial disparity |
| Austin 199010 | Median survival (years) | 117 | NYHSC + KCHC* | 49–92 | (<60) vs (>60) | Stage B–D | Decreases with age |
| Austin 199311 | Survival at 5 years (percent) | 914 | SEER* | 45–91 | (<60) vs (>60) | Stage B–D† | Decreases with age |
| Fowler 200012 | Cause specific survival (months after diagnosis) | 920 | VAMC* | Not reported | (<70) vs (>70) | Stage T1b-2 | Decreases with age |
| Matzkin 198313 | Overall survival | 119 | Not reported* | 49–86 | (<60) vs (>60) | Stage D2 | Decreases with age |
| Mebane 199014 | 5 year relative survival rate (percent) | 7.4% total Black population; 5% total White population | SEER* | Not reported | (50–59) (60–64) (65–69) (70–74) (75–79) (80–84) (85+) | All | Decreases with age |
| Pienta 199515 | Overall survival (months after diagnosis) | 12907 | SEER* | Not reported | (50) vs (55) vs (60) vs (65) vs (70) vs (75) | All | Decreases with age |
| Powell 199516 | Overall survival (months after diagnosis) | 741 | VAMC* | 43–96 | (<65) vs (>65) | All | Decreases with age |
| Kant 199217 | 5 year relative survival rate (proportion) | 127554 | SEER* | 19+ | (<65) vs (65–74) vs (75+) | All | Constant across age |
| Pulte 201218 | 5 year relative survival | Approx. 30 million | SEER* | Not reported | (15–64) vs (65+) | Not Reported | Constant across age |
| Walker 199519 | 5 year relative survival rate | Not reported | SEER* | Not reported | (<65) vs (>65) | Not Reported | Constant across age |
| Wingo 199820 | 5 year relative survival rate (percent) | 137888 | SEER* | Not reported | (45–54) (55–64) (65–74) (75+) | All | Constant across age |
| Penson 200721 | 5 year survival rate | Not Reported | SEER* | Not reported | (45–54) (55–64) (65–74) (75+) | All | Increases with age |
| MORTALITY | |||||||
| AuthorYear | Outcome | Sample | Data Source | Age Range | Age Comparisons | Staging | Racial Disparity Gap |
| Brawley 201222 | Mortality rates (per 100,000) | Not reported | SEER* | 40+ | (40–44) (45–49) (50–54) (55–59) (60–64) (65–69) (70–74) (75–79) (80–84) (85+) | Not Reported | Decreases with age |
| CDC 199223 | Death Rates (per 100,000) | Not reported | SEER* | 50+ | (50–54) (55–59) (60–64) (65–69) (70–74) (75–79) (80–84) (85+) | Not Reported | Decreases with age |
| Cheng 200924 | Deaths (percent) | 102691 | SEER* | 45+ | (45–54) (55–64) (65–74) (75–84) (85+) | All | Decreases with age |
| Chu 200325 | Mortality rates | 10% US Population | SEER* | 50–84 | (50–59) (60–69) (70–79) (80–84) (85+) | All | Decreases with age |
| Cowen 199426 | Annual mortality rates | Not reported | SEER* | 30–80 | (50) vs (55) vs (60) vs (65) vs (70) vs (75) vs (80) | Not reported | Decreases with age |
| Ernster 197727 | Mortality rates | 3258 | Alameda* | 50+ | (50–59) (60–64) (65–69) (70–74) (75+) | Not reported | Decreases with age |
| Ernster 197828 | Annual mortality rates | 106519 | Alameda* | 50+ | (50–59) (60–64) (65–69) (70–74) (70–79) (85+) | Not reported | Decreases with age |
| Fulton 200129 | Mortality rate | Not reported | RI, SEER* | 30+ | (30–39) (40–49) (50–59) 60–69) (70–79) (80+) | All | Decreases with age |
| Garfinkel 199430 | Mortality rates (per 100, 000) | US population | NCI* | Not reported | (<65) vs (>65) | Not reported | Decreases with age |
| Hsing 199431 | Mortality rates | Not reported | Nat Center for Health Stats* | 40+ | (40–49) (50–54) (55–59) (60–64) (65–69) (70–74) (75–79) (80–84) (85+) | Not reported | Decreases with age |
| Robbins 200032 | Death rate ratio | 23334 | SEER* | 35+ | (<65) vs (>65) | All | Decreases with age |
| Soto-Salgado 201233 | Mortality rate (per 100,000) | Not reported | SEER + PR* | 45+ | (45–54) (55–64) (65–74) (75–84) (85+) | Not reported | Decreases with age |
| Datta 201134 | Odds ratio for mortality | 5% US Census Microsample Data | US Census | 40–89 | (40–64) vs (65–74) vs (75+) | All | Constant across age |
| Merrill 199735 | Percent mortality (years after diagnosis) | 10% US population | SEER* | 50+ | (50–69) vs (70+) | All | Constant across age |
| Piffath 200136 | Mortality rate (per 100,000) | Not reported | Vital Stats of US Reports | 40+ | (60–69) (70–79) (80+) | Not reported | Constant across age |
| Sarma 200237 | Lifetime risk for dying | 10% US Population | SEER* | Not reported | (50) vs (60) vs (70) | All | Constant across age |
*
Alameda: Alameda County; KCHC: Kings County Hospital Center; NYHSC: New York Health Science Center; Nat Center for Health Stats: National Center for Health Statistics; NCI: National Cancer Institute Cancer Statistics Review; PR: Puerto Rico Central Cancer Registry; RI: Rhode Island Cancer Registry; SEER: Surveillance, Epidemiology, and End Results Program; VAMC: Veterans Affairs Medical Center
†
554 cases lack report on staging